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Cytology and fine needle aspiration biopsy in the diagnosis of lung 
cancer
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Conventional cytology such as sputum, bronchial brushes, washes 
and lavages and ﬁne needle aspiration biospy (FNA) have long played 
a role in the diagnosis of primary and metastatic lung cancers. The 
separation of small cell lung cancer from non small cell lung can-
cer (NSCLC), especially in cytologic material, has historically been 
deemed sufﬁcient for purposes of patient treatment. Small cell carcino-
ma was treated by chemotherapy and NSCLC underwent surgery ﬁrst 
and then chemotherapy where appropriate. The separation of NSCLC 
into adenocarcinoma and its subtypes and squamous cell carcinomas 
was not necessary. In the era of targeted therapy this approach is no 
longer adequate.
Cytologic preparations can allow the distinction of adenocarcinoma 
subtypes, particularly bronchioloalveolar, and the recognition of squa-
mous cell carcinoma.
The use of immunohistochemical stains such as TTF-1, CK7, CK20, 
4A4, 34βE12 and p63 can be applied to cytologic material to help 
make these distinctions. In additon, cytology material such as cells 
blocks can be utilzed for EGFR gene mutation studies.
Speciﬁc cytologic ﬁndings associated with the presence of BAC or 
adenocarcinoma with a BAC component can be identiﬁed in cytologic 
preparatins. These ﬁndings include ﬂat sheets of epithelial cells, nuclear 
inclusions and grooves and lack of prominent nucleoli.
The role of cytology in the diagnosis and management of lung cancer is 
of increasing importance and cytology can be used to provide excellent 
and accurate classiﬁcations of lung tumors. 
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Intra-operative pathology consultation - novel approaches to frozen 
section
Nicholson, Andrew G. 
Professor of Respiratory Pathology, National Heart and Lung Division 
of Imperial College School of Medicine, London, UK
Undertaking frozen sections (FSs) is a well-established and diagnosti-
cally accurate procedure that aids in the intra-operative staging of 
many cancers (1). The European Society of Thoracic Surgeons (ESTS) 
have recently published guidelines relating to intraoperative lymph 
node staging, and the pathologic evaluation of resected lymph nodes 
in patients with non-small cell lung cancer (NSCLC) with the aim of 
standardising management (2). A standardised approach to FS analysis 
of bronchial resection margins has also been recently proposed that 
highlights the difference between direct growth of invasive non-small 
cell carcinoma, lymphangitic spread and carcinoma-in situ (3)
In an effort to reﬁne the above, there have also been recent studies 
assessing whether identiﬁcation of sentinel nodes for frozen section 
may inﬂuence extent of resection and number of nodes required to be 
assessed during operation, with varying degrees of success (4,5).
The increased reﬁnement of adenocarcinoma diagnosis in relation to 
the patterns identiﬁed in the WHO classiﬁcation (6) and the Noguchi 
classiﬁcation (7) has also led to groups assessing how far this can be 
taken at FS, as limited resection could be an acceptable alternative for 
some patients with ÎearlyÌ disease. One study has shown that, in small 
(< or = 10 mm) peripheral adenocarcinomas, FS may be used to apply 
Noguchi’s classiﬁcation, particularly types A and B, in which there may 
be intent to limited surgery (8). Using imprint cytology, there are also 
cytological factors that can predict invasion in small-sized peripheral 
lung adenocarcinoma with a bronchioloalveolar carcinoma component. 
In one study, univariate analysis identiﬁed ﬁve cytologic factors that 
were associated signiﬁcantly with invasion (presence of tumour clusters 
comprising more than 50 tumour cells, nuclear overlap in more than 
three layers, presence of nuclear grooves, more than 3-fold variation 
in nuclear size, and 1 mitosis per 1000 tumour cells). Among these, 
nuclear overlapping in more than three layers and more than 3-fold 
variation in nuclear size were found to be independent predictive fac-
tors for invasion by multivariate analysis (9).
Another problem area, particularly in the lung, is when there is a his-
tory of previous malignancy. Differentiating primary from metastatic 
carcinomas can be difﬁcult, especially with poorer morphology on FS 
and no histological feature is 100% speciﬁc (10). In parafﬁn-embedded 
tissue, an immunohistochemical panel is typically used to in addition 
to morphology to assess cytokeratin proﬁles (e.g. 7 and 20) and the 
presence/absence of more organ-speciﬁcÌ epitopes such as thyroid tran-
scription factor-1 (TTF-1) and hormone receptors. Of these TTF-1 is 
the most valuable as it is highly speciﬁc and sensitive for primary lung 
tumours, excluding thyroid neoplasms (11,12). The ability to undertake 
intra-operative immunohistochemstry would therefore be of potential 
value as distinction of the type of tumour at this timepoint could inﬂu-
ence surgery (anatomic resection for primary lung cancer and more 
localised resection for metastatic disease) (13,14) and methodology that 
permits this within the timeframe of a thoracotomy and with similar 
speciﬁcity and sensitivity to that seen for formalin-ﬁxed tissues has 
recently become available (FSIHC) (15).
In a prospective study over two years, this additional immunohisto-
chemical data at the time of operation increased diagnostic conﬁdence 
in all cases, particularly in cases that were positive for TTF-1 (16). 
